News

FDA Turns Down Novel Antidiabetes Drug


 

Susan Holz, public relations manager at Boehringer Ingelheim Pharmaceuticals, said in an earlier interview, "We are aware of the advisory committee’s concerns with dapagliflozin and are working with the FDA to ensure [that] our filing package for empagliflozin is robust and comprehensive. Phase III trials for empagliflozin are underway, and we are continuing to evaluate the drug’s safety profile." Currently, there are 11 ongoing, multinational, phase III clinical trials, including a large cardiovascular outcomes safety trial, she said.

At the EASD meeting in September, Dr. Michaela Diamant, scientific director of the diabetes center at Free University Medical Center in Amsterdam, commented that SGLT2 inhibitors have "an interesting mechanism that addresses, to a certain extent, a pathogenic defect that has been largely overlooked in diabetes. ... I’m sure there is a huge group of patients who can profit from these novel agents."

Regarding the safety issue, she asked, "If you would have a trial of 2-5 years, would you definitely address causality of cancer? We know that cancer development takes 20 years. It’s very unlikely that the drug caused cancer. We have to do what is feasible. The industry is not going to develop any more of these drugs if they are required to do a trial of 10 years. It’s difficult to tease out [contributors] to the development of cancer," Dr. Diamant continued.

Dr. Diamant has been a board member, advisory panel member, consultant, research support recipient, and/or speakers bureau participant for Eli Lilly, Merck Sharp & Dohme, Novo Nordisk, Abbott, AstraZeneca/BMS, Boehringer Ingelheim, Poxel Pharma, Sanofi-Aventis, Amylin Pharmaceuticals, Novartis, and Takeda.

Sue Sutter of "The Pink Sheet" contributed to this story. "The Pink Sheet" and this publication are both owned by Elsevier.

Pages

Recommended Reading

Weight Loss Modest With Primary Care Program
MDedge Cardiology
Doctors Advised to Test Cholesterol in All Children Aged 9-11 Years
MDedge Cardiology
Remote Weight-Loss Program Effective Long-Term
MDedge Cardiology
For Most With Diabetes, Revascularization Can Wait
MDedge Cardiology
HPS: Benefits, Safety Persist With Long-Term Statin Use
MDedge Cardiology
Undiagnosed Diabetes Common in Women With Acute MI
MDedge Cardiology
LDL Cholesterol, Systolic Blood Pressure Predict Different CV Events
MDedge Cardiology
CPAP Improves Metabolic Syndrome in Apnea Patients
MDedge Cardiology
Physicians Integral in Battling Diabetes Epidemic
MDedge Cardiology
Obesity in U.S. Appears to Be Leveling Off
MDedge Cardiology